SMS1 also exhibits weak phosphatidylethanolamine (PE)-PLC activity, though 300-fold lower than its SM synthase activity .
Sphingolipid Homeostasis: SMS1 counteracts ceramide accumulation by converting it to SM, thereby regulating apoptosis and cell proliferation .
Oncogenic Signaling: In chronic myelogenous leukemia (CML), Bcr-Abl upregulates SMS1 transcription 30-fold and shifts its transcription start site (TSS), enhancing translational efficiency by 20-fold. This drives SM synthesis and leukemic cell survival .
Protein Trafficking: SMS1-derived DAG recruits protein kinase D (PKD) to the Golgi, facilitating TGN-to-plasma membrane vesicle fission. SMS1 knockdown disrupts insulin secretion in pancreatic β-cells .
Catalytic Mechanism: SMS1 operates via a two-step process:
Membrane Topology: The catalytic site faces the Golgi lumen, ensuring SM synthesis occurs in the exoplasmic leaflet .
Disease Relevance:
Pharmacological Targeting:
| Feature | SMS1 | SMS2 |
|---|---|---|
| Localization | Golgi apparatus | Golgi and plasma membrane |
| Primary Activity | SM synthesis | SM synthesis + PE→CPE conversion |
| PC-PLC Activity | Moderate (Km = 62.3 µM) | High (Km = 48.9 µM) |
| Role in Trafficking | Critical for PKD recruitment | Minor role |